Submissions for variant NM_005633.4(SOS1):c.508A>G (p.Lys170Glu)

dbSNP: rs397517172

Total submissions: 19

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen RASopathy Variant Curation Expert Panel	RCV000038560	SCV000616383	pathogenic	Noonan syndrome	2017-04-03	reviewed by expert panel	curation	The c.508A>G (p.Lys170Glu) variant in SOS1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 19020799, 21387466). In vitro functional studies provide some evidence that the p.Lys170Glu variant may impact protein function (PS3; PMID 21784453, 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Lys170Glu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6, PS3.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000038560	SCV000062238	pathogenic	Noonan syndrome	2011-09-26	criteria provided, single submitter	clinical testing	The Lys170Glu has been reported in four individuals with clinical features of No onan syndrome (Ko 2008, Lee 2011, Lepri 2011). In addition, this variant has occ urred de novo in two individuals (Ko 2008, LMM unpublished data). Furthermore, functional data indicates that this variant leads to gain-of-function (Lee 2011) , which is an established pathogenic mechanism in Noonan syndrome. In summary, t his variant meets our criteria to be classified as pathogenic (http://pcpgm.part ners.org/LMM).
GeneDx	RCV000157689	SCV000209094	pathogenic	not provided	2023-03-27	criteria provided, single submitter	clinical testing	Published functional studies demonstrate enhanced activity of the Ras-MAPK pathway (Smith et al., 2013; Lee et al., 2011); Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 21387466, 23487764, 19020799, 21784453, 24803665, 26918529, 34008892, 32333414, 35986401, 34643321, 35979676, 34163525, 29493581, 35770001, 35188046, 33677855)
Invitae	RCV000476014	SCV000553270	pathogenic	RASopathy	2023-10-30	criteria provided, single submitter	clinical testing	This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 170 of the SOS1 protein (p.Lys170Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Noonan syndrome (PMID: 19020799, 19953625, 21387466). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 40651). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects SOS1 function (PMID: 21784453). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics	RCV000624105	SCV000741316	pathogenic	Inborn genetic diseases	2016-02-19	criteria provided, single submitter	clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV001002150	SCV001160005	pathogenic	not specified	2018-09-25	criteria provided, single submitter	clinical testing	The SOS1 c.508A>G; p.Lys170Glu variant (rs397517172), is reported in the literature in multiple individuals affected with Noonan syndrome (Denayer 2010, Ko 2008, Lepri 2011). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 40651), and is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. Functional analyses of the variant protein shows increased activation of Ras and ERK, due to structural changes in the autoinhibitory HF domain (Lee 2011, Smith 2013). The lysine at codon 170 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Based on available information, the p.Lys170Glu variant is considered to be pathogenic. References: Denayer E et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer. 2010 Mar;49(3):242-52. Ko JM et al. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet. 2008;53(11-12):999-1006. Lee BH et al. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr. 2011 Dec;159(6):1029-35. Lepri F et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat. 2011 Jul;32(7):760-72. Smith MJ et al. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000476014	SCV001363487	pathogenic	RASopathy	2021-07-27	criteria provided, single submitter	clinical testing	Variant summary: SOS1 c.508A>G (p.Lys170Glu) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251282 control chromosomes. c.508A>G has been reported in the literature in multiple individuals affected with Noonan Syndrome And Related Conditions (e.g. Ko_2008, Denayer_2010, Lepri_2011, vanTrier_2015). These data indicate that the variant is very likely to be associated with disease. Two functional studies showed that this variant had a gain-of-function effect (Lee_2011, Smith_2013). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne	RCV001526618	SCV001737048	pathogenic	Neonatal hypotonia		criteria provided, single submitter	research
Laboratory of Medical Genetics, National & Kapodistrian University of Athens	RCV001729357	SCV001976660	pathogenic	Noonan syndrome 4	2021-10-01	criteria provided, single submitter	clinical testing	PM2, PP2, PP3, PP5
Neuberg Supratech Reference Laboratories Pvt Ltd, Neuberg Centre for Genomic Medicine	RCV001729357	SCV002073352	pathogenic	Noonan syndrome 4		criteria provided, single submitter	clinical testing	The missense variant p.K170E in SOS1 (NM_005633.4) has been previously reported in multiple patients with Noonan syndrome. Functional studies depict a damaging effect (Smith MJ et al; Lee BH et al). The variant has been submitted to Clinvar as Pathogenic and has been reviewed by an expert Rasopathy curator panel. The p.K170E variant is novel (not in any individuals) in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. The p.K170E missense variant is predicted to be damaging by both SIFT and PolyPhen2. The lysine residue at codon 170 of SOS1 is conserved in all mammalian species. The nucleotide c.508 in SOS1 is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
Institute for Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin	RCV001729357	SCV002574849	pathogenic	Noonan syndrome 4	2022-09-22	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV002345263	SCV002646037	pathogenic	Cardiovascular phenotype	2021-12-27	criteria provided, single submitter	clinical testing	The p.K170E pathogenic mutation (also known as c.508A>G), located in coding exon 4 of the SOS1 gene, results from an A to G substitution at nucleotide position 508, which is located in the histine-like folds domain. The lysine at codon 170 is replaced by glutamic acid, an amino acid with some similar properties. This alteration has been reported in multiple individuals with a clinical diagnosis of Noonan syndrome, including several cases described as de novo; clinical details were limited in some individuals (Ko JM et al. J. Hum. Genet., 2008 Dec;53:999-1006; Denayer E et al. Genes Chromosomes Cancer, 2010 Mar;49:242-52;; Lepri F et al. Hum Mutat, 2011 Jul;32:760-72; Shoji Y et al. Endocr J, 2019 Nov;66:983-994; Deden C et al. Prenat Diagn, 2020 07;40:972-983). Two in vitro functional studies have found this alteration results in significantly increased activation of the Ras pathway (Lee BH et al. J Pediatr. 2011;159(6):1029-35; Smith MJ et al. Proc Natl Acad Sci USA. 2013;110(12):4574-9). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein	RCV001729357	SCV003807612	pathogenic	Noonan syndrome 4	2022-06-07	criteria provided, single submitter	clinical testing	ACMG classification criteria: PS3 strong, PM1 moderated, PM2 moderated, PM6 moderated, PP2 supporting, PP3 supporting
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden	RCV000157689	SCV004026039	pathogenic	not provided	2022-04-05	criteria provided, single submitter	clinical testing	PM1, PS3, PM6, PP3, PP2, PM2_SUP
PreventionGenetics, part of Exact Sciences	RCV003914900	SCV004737506	pathogenic	SOS1-related condition	2024-02-18	criteria provided, single submitter	clinical testing	The SOS1 c.508A>G variant is predicted to result in the amino acid substitution p.Lys170Glu. This variant has been reported in at least six individuals with Noonan syndrome and has been reported as a likely de novo variant in at least two of these cases (Ko et al. 2008. PubMed ID: 19020799; Denayer et al. 2010. PubMed ID: 19953625; Lepri et al. 2011. PubMed ID: 21387466; Hakami et al. 2016. PubMed ID: 26918529). Additionally, functional studies demonstrate this variant results in increased RAS activation, p-ERK levels, and GDP-to-GTP exchange rate, consistent with a gain-of-function mechanism, resulting in hyperactivation of the RAS pathway (Lee et al. 2011. PubMed ID: 21784453; Smith et al. 2013. PubMed ID: 23487764). This variant has not been reported in a large population database, indicating this variant is rare and has been interpreted by multiple labs as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/40651/). Based on the available data, we classify the SOS1 c.508A>G (p.Lys170Glu) variant to be pathogenic.
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center	RCV000157689	SCV000207673	pathogenic	not provided	2015-01-15	no assertion criteria provided	clinical testing
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen	RCV000157689	SCV001744484	pathogenic	not provided		no assertion criteria provided	clinical testing
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)	RCV000157689	SCV001798822	likely pathogenic	not provided		no assertion criteria provided	clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	RCV000157689	SCV001958338	pathogenic	not provided		no assertion criteria provided	clinical testing